Immuneering Q1 net loss $13.6M; positive Phase 1 data for IMM-1-104 accelerates timeline

Immuneering Corp

2023-Q1 EPS reported -$0.51

Net loss $13.6M ($0.51/sh) for Q1 2023; cash & equivalents $91.5M as of Mar 31, 2023.
Positive initial Phase 1 PK, PD, safety data for IMM-1-104: significant PK Cmax, ~2h half-life, no DLTs.
RP2D expected early 2024 (accelerated); potential to assess preliminary efficacy sooner than anticipated.
Completed $30M stock offering (2.73M shares at $11.00); cash runway extended into 2025.
Appointed Harold E. Brakewood as CBO in March 2023; IND for IMM-6-415 expected Q4 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Immuneering Corp reported the first quarter ended March 31, 2023 results: net income $13.6 million, EPS $0.51 per share.

Period: the first quarter ended March 31, 2023
Net income: $13.6 million
EPS: $0.51 per share
Result: reported results

Exact text from the filing

Net loss attributable to common stockholders was $13.6 million, or $0.51 per share, for the first quarter ended March 31, 2023, compared to $12.9 million, or $0.49 per share, for the first quarter ended March 31, 2022.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Immuneering Corp filing history →

Source: SEC EDGAR

accession 0001790340-23-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.